Verrica Pharmaceuticals Inc Forecast, price target & analysts
Verrica Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Verrica Pharmaceuticals Inc Classifications & Recommendation:
Verrica Pharmaceuticals Inc Price Target
| Target Price | $3.33 |
| Price | $0.59 |
| Potential |
464.88%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Verrica Pharmaceuticals Inc 2026 .
The average Verrica Pharmaceuticals Inc target price is $3.33.
This is
464.88%
register free of charge
$5.00
747.31%
register free of charge
$2.00
238.93%
register free of charge
|
|
| A rating was issued by 5 analysts: 2 Analysts recommend Verrica Pharmaceuticals Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Verrica Pharmaceuticals Inc stock has an average upside potential 2026 of
464.88%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 5.12 | 8.25 |
| 43.30% | 61.22% | |
| EBITDA Margin | -1,218.55% | -702.46% |
| 434.67% | 42.35% | |
| Net Margin | -1,318.13% | -798.80% |
| 262.53% | 39.40% |
5 Analysts have issued a sales forecast Verrica Pharmaceuticals Inc 2024 . The average Verrica Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Verrica Pharmaceuticals Inc 2024 . The average Verrica Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Verrica Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Verrica Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.48 | -1.45 |
| 105.56% | 2.03% | |
| P/E | negative | |
| EV/Sales | 9.40 |
5 Analysts have issued a Verrica Pharmaceuticals Inc forecast for earnings per share. The average Verrica Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Verrica Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Verrica Pharmaceuticals Inc...
Current Verrica Pharmaceuticals Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham | Locked ➜ Locked | Locked | Dec 20 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 06 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 05 2024 |
| RBC Capital | Locked ➜ Locked | Locked | Nov 05 2024 |
| TD Cowen | Locked ➜ Locked | Locked | Oct 21 2024 |
| RBC Capital | Locked ➜ Locked | Locked | Oct 04 2024 |
| Needham | Locked ➜ Locked | Locked | Oct 03 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham: Locked ➜ Locked
|
Dec 20 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 06 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 05 2024 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Nov 05 2024 |
|
Locked
TD Cowen: Locked ➜ Locked
|
Oct 21 2024 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Oct 04 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Oct 03 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
